Director, HTA, Value & Evidence (HV&E), I&I / Brepocitinib (Med Rheum)

The Director, Value & Evidence - Brepocitinib will support the strategic goals of the Inflammation & Immunology Business Unit by driving optimal launch and patient access for Brepocitinib through the generation, integration, and translation of robust value and evidence. This role directly impacts Pfizer's ability to achieve global access and reimbursement objectives by providing strategic leadership and execution of Health Technology Assessment, Value & Evidence (HV&E) activities that demonstra…